NervGen Pharma Valuation
| NGENF Stock | USD 2.03 0.03 1.50% |
Based on Macroaxis valuation methodology, the firm appears to be overvalued. NervGen Pharma Corp secures a last-minute Real Value of $1.59 per share. The latest price of the firm is $2.03. Our model forecasts the value of NervGen Pharma Corp from analyzing the firm fundamentals such as Current Valuation of 48.78 M, return on equity of -1.42, and Shares Owned By Insiders of 25.27 % as well as examining its technical indicators and probability of bankruptcy. . In general, most investors recommend locking in undervalued stocks and disposing overvalued stocks since, at some point, asset prices and their ongoing real values will merge together.
Overvalued
Today
Please note that NervGen Pharma's price fluctuation is dangerous at this time. Calculation of the real value of NervGen Pharma Corp is based on 3 months time horizon. Increasing NervGen Pharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the NervGen otc stock is determined by what a typical buyer is willing to pay for full or partial control of NervGen Pharma Corp. Since NervGen Pharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of NervGen OTC Stock. However, NervGen Pharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.03 | Real 1.59 | Hype 2.03 | Naive 2.19 |
The real value of NervGen OTC Stock, also known as its intrinsic value, is the underlying worth of NervGen Pharma Corp OTC Stock, which is reflected in its stock price. It is based on NervGen Pharma's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of NervGen Pharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of NervGen Pharma Corp helps investors to forecast how NervGen otc stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of NervGen Pharma more accurately as focusing exclusively on NervGen Pharma's fundamentals will not take into account other important factors: NervGen Pharma Total Value Analysis
NervGen Pharma Corp is now estimated to have takeover price of 48.78 M with market capitalization of 87.43 M, debt of 324.69 K, and cash on hands of 11.65 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the NervGen Pharma fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
48.78 M | 87.43 M | 324.69 K | 11.65 M |
NervGen Pharma Asset Utilization
One of the ways to look at asset utilization of NervGen is to check how much profit was generated for every dollar of assets it reports. NervGen Pharma Corp secures a negative usage of assets of -0.67 %, losing $0.006661 for each dollar of assets held by the firm. Inadequate asset utilization conveys that the company is being less effective with each dollar of assets it secures. Strictly speaking, asset utilization of NervGen Pharma Corp shows how discouraging it operates for each dollar spent on its assets.NervGen Pharma Ownership Allocation
NervGen Pharma Corp maintains a total of 58.68 Million outstanding shares. NervGen Pharma Corp holds significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.NervGen Pharma Profitability Analysis
Net Loss for the year was (12.73 M) with profit before overhead, payroll, taxes, and interest of 0.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates NervGen Pharma's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in NervGen Pharma and how it compares across the competition.
About NervGen Pharma Valuation
The otc valuation mechanism determines NervGen Pharma's current worth on a weekly basis. Our valuation model uses a comparative analysis of NervGen Pharma. We calculate exposure to NervGen Pharma's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of NervGen Pharma's related companies.NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. NervGen Pharma Corp. was incorporated in 2017 and is based in Vancouver, Canada. NERVGEN PHARMA operates under Biotechnology classification in the United States and is traded on OTC Exchange.
8 Steps to conduct NervGen Pharma's Valuation Analysis
OTC Stock's valuation is the process of determining the worth of any otc stock in monetary terms. It estimates NervGen Pharma's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of otc stock valuation is a single number representing a OTC Stock's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct NervGen Pharma's valuation analysis, follow these 8 steps:- Gather financial information: Obtain NervGen Pharma's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine NervGen Pharma's revenue streams: Identify NervGen Pharma's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research NervGen Pharma's industry and market trends, including the size of the market, growth rate, and competition.
- Establish NervGen Pharma's growth potential: Evaluate NervGen Pharma's management, business model, and growth potential.
- Determine NervGen Pharma's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the OTC Stock's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate NervGen Pharma's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
NervGen Pharma Growth Indicators
Investing in growth stocks can be very risky. If the company such as NervGen Pharma does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 46.2 M | |
| Retained Earnings | -35 M |
Complementary Tools for NervGen OTC Stock analysis
When running NervGen Pharma's price analysis, check to measure NervGen Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NervGen Pharma is operating at the current time. Most of NervGen Pharma's value examination focuses on studying past and present price action to predict the probability of NervGen Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NervGen Pharma's price. Additionally, you may evaluate how the addition of NervGen Pharma to your portfolios can decrease your overall portfolio volatility.
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |